Share on LinkedInShare on LinkedIn

ARTICLE · 10 JANUARY 2018

Clinical Trial Hypothesis Doesn't Constitute Reasonable Expectation Of Success

After a bench trial, the district court found infringement and rejected defendants' obviousness argument. Defendants appealed.

United StatesIntellectual Property

Addressing the issues of reasonable expectation of success and induced infringement of claims directed to a method of treatment in a particular patient population based on the results of a clinical trial, the US Court of Appeals for the Federal Circuit upheld the district court's finding that the claimed method was not obvious and that language in the proposed package inserts induced infringement. Sanofi v. Watson Labs Inc., Case Nos. 16-2722; -2726 (Fed. Cir., Nov. 9, 2017) (Taranto, J). 

Watson and Sandoz filed abbreviated new drug applications seeking to market generic versions of Sanofi's Multaq®. Sanofi sued, alleging infringement of a patent directed to decreasing a risk of cardiovascular hospitalization in patients meeting certain clinical criteria by administering dronedarone—the active ingredient in Multaq®. After a bench trial, the district court found infringement and rejected defendants' obviousness argument. Defendants appealed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from